ILK and PRDX1 Are Prognostic Markers in Squamous Cell/adenosquamous Carcinomas and Adenocarcinoma of Gallbladder

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2012 Oct 16

PMID 23065574

Citations 13

Authors

Jinghe Li

Zhu-Lin Yang

Xuebao Ren

Qiong Zou

Yuan Yuan

Lufeng Liang

Meigui Chen

Senlin Chen

Affiliations

Soon will be listed here.

Abstract

Although the incidence of gallbladder cancers is low, they are highly aggressive tumors. Squamous cell/adenosquamous carcinoma (SC/ASC) is a rare subtype of gallbladder cancer. The clinical characteristics of SC/ASC have not been well documented, and no prognosis marker has been identified. In this study, we examined integrin-linked kinase (ILK) and peroxiredoxin-1 (PRDX1) expression in 46 SC/ASCs and 80 adenocarcinomas (ACs) by using immunohistochemistry and analyzed their correlations with clinicopathological characteristics. We demonstrated that positive ILK and PRDX1 expressions were significantly associated with large tumor size, high TNM stage, lymph node metastasis, and invasion of SC/ASC and AC. Univariate Kaplan-Meier analysis showed that positive ILK and PRDX1 expressions were closely associated with decreased overall survival in both SC/ASC (p < 0.001 and p = 0.005, respectively) and AC (p < 0.001) patients. Multivariate Cox regression analysis showed that positive ILK and PRDX1 expressions were an independent poor prognostic predictor in both SC/ASC and AC patients. We also revealed a similar significance of differentiation, tumor size, TNM stage, lymph node metastasis, invasion, and surgical curability with survival in SC/ASC and AC patients. Our study suggested that positive ILK and PRDX1 expressions are closely related to the progression and poor prognosis of gallbladder cancer.

Citing Articles

Therapeutic response analysis for patients with adenosquamous carcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database.

Fang S, Wang X, Wu X, Li H J Gastrointest Oncol. 2023; 14(1):405-419.

PMID: 36915441 PMC: 10007914. DOI: 10.21037/jgo-22-1292.

Proteomic profiling of cell line-derived extracellular vesicles to identify candidate circulatory markers for detection of gallbladder cancer.

Priya R, Jain V, Akhtar J, Saklani N, Sakhuja P, Agarwal A Front Oncol. 2022; 12:1027914.

PMID: 36505879 PMC: 9727277. DOI: 10.3389/fonc.2022.1027914.

Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study.

Jiao L, Wei J, Ye J, Zhang C Dis Markers. 2021; 2021:9508702.

PMID: 33747258 PMC: 7952178. DOI: 10.1155/2021/9508702.

Comparative Outcomes of Adenosquamous Carcinoma of the Gallbladder: an Analysis of the National Cancer Database.

Murimwa G, Hester C, Mansour J, Polanco P, Porembka M, Wang S J Gastrointest Surg. 2020; 25(7):1815-1827.

PMID: 32705618 DOI: 10.1007/s11605-020-04729-w.

Clinicopathological features and survival of gallbladder squamous cell carcinoma: analysis of 121 cases.

Zou X, Wang J, Jiang Y, Chen G, Mo W, Feng Z Int J Clin Exp Pathol. 2020; 11(7):3208-3221.

PMID: 31949696 PMC: 6962876.

References

Jayaraman S, Jarnagin W . Management of gallbladder cancer. Gastroenterol Clin North Am. 2010; 39(2):331-42, x. DOI: 10.1016/j.gtc.2010.02.006. View

Hawkins W, DeMatteo R, Jarnagin W, Ben-Porat L, Blumgart L, Fong Y . Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004; 11(3):310-5. DOI: 10.1245/aso.2004.03.011. View

OOTANI T, Shirai Y, Tsukada K, Muto T . Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992; 69(11):2647-52. DOI: 10.1002/1097-0142(19920601)69:11<2647::aid-cncr2820691105>3.0.co;2-0. View

Liu D, Yang Z, Jiang S . Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. Cancer Biomark. 2011; 8(3):113-21. DOI: 10.3233/DMA-2011-0812. View

Hoshino I, Matsubara H, Akutsu Y, Nishimori T, Yoneyama Y, Murakami K . Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients. Oncol Rep. 2007; 18(4):867-71. View

Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H . Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene. 2006; 25(23):3237-46. DOI: 10.1038/sj.onc.1209356. View

Chung K, Lee D, Kim Y, Kim T, Huh J, Chung S . Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2009; 9(1):451-7. DOI: 10.1021/pr900811x. View

Prosperi M, Ferbus D, Karczinski I, Goubin G . A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins. J Biol Chem. 1993; 268(15):11050-6. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

10.

Cortez V, Nair B, Chakravarty D, Vadlamudi R . Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed). 2011; 3(2):788-96. PMC: 3243948. DOI: 10.2741/s187. View

11.

Reid K, Ramos-De la Medina A, Donohue J . Diagnosis and surgical management of gallbladder cancer: a review. J Gastrointest Surg. 2007; 11(5):671-81. DOI: 10.1007/s11605-006-0075-x. View

12.

Durbin A, Hannigan G, Malkin D . Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle. 2009; 8(24):4060-6. DOI: 10.4161/cc.8.24.10093. View

13.

Quan C, Cha E, Lee H, Han K, Lee K, Kim W . Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006; 175(4):1512-6. DOI: 10.1016/S0022-5347(05)00659-2. View

14.

Maxwell G, Hood B, Day R, Chandran U, Kirchner D, Kumar Kolli V . Proteomic analysis of stage I endometrial cancer tissue: identification of proteins associated with oxidative processes and inflammation. Gynecol Oncol. 2011; 121(3):586-94. PMC: 7294860. DOI: 10.1016/j.ygyno.2011.02.031. View

15.

Kim J, Bogner P, Baek S, Ramnath N, Liang P, Kim H . Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008; 14(8):2326-33. DOI: 10.1158/1078-0432.CCR-07-4457. View

16.

Mu Z, Yin X, Prochownik E . Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression. J Biol Chem. 2002; 277(45):43175-84. DOI: 10.1074/jbc.M206066200. View

17.

Wen S, Van Etten R . The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 1997; 11(19):2456-67. PMC: 316562. DOI: 10.1101/gad.11.19.2456. View

18.

McDonald P, Fielding A, Dedhar S . Integrin-linked kinase--essential roles in physiology and cancer biology. J Cell Sci. 2008; 121(Pt 19):3121-32. DOI: 10.1242/jcs.017996. View

19.

Graff J, Deddens J, Konicek B, Colligan B, Hurst B, CARTER H . Integrin-linked kinase expression increases with prostate tumor grade. Clin Cancer Res. 2001; 7(7):1987-91. View

20.

de Aretxabala X, Roa I, Burgos L, Losada H, Roa J, Mora J . Gallbladder cancer: an analysis of a series of 139 patients with invasion restricted to the subserosal layer. J Gastrointest Surg. 2006; 10(2):186-92. DOI: 10.1016/j.gassur.2005.11.003. View